Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Volume Increase – Here’s Why

by · The Markets Daily

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw unusually-strong trading volume on Wednesday . Approximately 162,046 shares were traded during trading, an increase of 225% from the previous session’s volume of 49,907 shares.The stock last traded at $14.03 and had previously closed at $13.63.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Read Our Latest Stock Analysis on Fresenius SE & Co.

Fresenius SE & Co. Stock Performance

The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.99 and a current ratio of 1.26. The firm’s fifty day simple moving average is $14.77 and its 200 day simple moving average is $13.57.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.02. Fresenius SE & Co. had a net margin of 5.26% and a return on equity of 9.72%. The company had revenue of $6.29 billion during the quarter, compared to analysts’ expectations of $6.38 billion. On average, analysts forecast that Fresenius SE & Co. will post 0.79 EPS for the current year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Further Reading